About Us


image

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

Resources

Patient Support Center

www.KaryForward.com   

1 877 KARY4WD (1 877 527 9493)

Contact Us!

85 Wells Ave Ste. 210

Newton, MA 02459

Patient Support Center
Karyforward.com  1 877 KARY4WD (1 877 527 9493)

Medical Information
medicalinformation@karyopharm.com  
888-209-9326

Kalin Bird
Kalin.Bird@karyopharm.com
571-292-7766
 
Tara Forth
tforth@karyopharm.com
681-404-2248
 
Kelly Steinhauser 
ksteinhauser@karyopharm.com
316-558-0258